- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01603108
Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant (Rifaximin)
Prospective Randomized Double Blind Placebo Controlled Trial of Rifaximin 550mg PO Twice Daily for Three Months to Prevent Recurrent Fibrosis in Liver Transplant Recipients With Chronic Hepatitis C Virus Infection
The purpose of this study is to determine if the administration of a poorly-absorbable antibiotic (rifaximin) for the first three months after liver transplant will reduce the amount of fibrosis (or scarring of the liver) in liver transplant patients with recurrent hepatitis C virus (HCV) by lowering serum lipopolysaccharide (LPS), a protein in blood that comes from the bacteria in intestines and may cause scarring in the liver.
Approximately 60 subjects will participate in this study. Subjects will be part of the study for approximately 1 year post transplant.
Studieoversigt
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
New York
-
New York, New York, Forenede Stater, 10032
- Columbia University Medical Center - NYPH
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Subject must provide written informed consent before any study assessment is performed
- Age ≥ 18 years
- Willing and able to sign informed consent
- Chronic HCV infection with viremia
- Listed for liver transplantation
- Demonstrate ability to take oral medications prior to randomization (post LT)
Exclusion Criteria:
- Age < 18 years old
- Unwilling/able to sign informed consent
- Cleared HCV infection (and therefore not at risk for recurrent HCV)
- Human immunodeficiency virus (HIV) co-infection
- Hepatitis B (HBV) co-infection
- Participation in another interventional clinical trial
- Females of childbearing (reproductive) potential must have a negative serum pregnancy test at Screening and agree to use an acceptable method of contraception throughout their participation in the study
- Subjects with history of hypersensitivity to rifaximin, rifampin, rifamycin antimicrobial agents, or any of the components of rifaximin
- Subjects with history of tuberculosis infection or has received treatment for tuberculosis infection. If subject has previous positive test for tuberculosis antigen then they must have current negative chest x-ray to be eligible
- Subject has diarrhea and positive Clostridium difficile (C. difficile) toxin via stool examination during Screening period. NOTE: Stool examination for C. difficile toxin will be performed on subjects who have diarrhea during the screening period. Results of stool tests should be confirmed as negative prior to randomization
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Rifaximin Arm
Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet.
Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
|
Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet.
Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
Andre navne:
|
Placebo komparator: Placebo Control Arm
Rifaximin placebo will be initiated post-LT, once the subject is able to tolerate oral medications/diet.
Rifaximin placebo will be taken twice daily for 90 days (+/- 10 days) post-LT.
|
Rifaximin placebo will be initiated post LT, once the subject is able to tolerate oral medications/diet.
Rifaximin placebo dosed at 550 mg twice daily for 90 days (+/10 days) post LT.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Significant recurrence of Hepatitis C
Tidsramme: One year post liver transplant
|
Significant recurrence of hepatitis C at one year post-LT defined as at least stage 2 fibrosis, fibrosing cholestatic hepatitis or death/graft failure due to HCV.
|
One year post liver transplant
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Measurement of Serum LPS
Tidsramme: 3 months and 12 months post liver transplant
|
Comparison of serum LPS measurements between groups, to determine if the use of rifaximin is associated with reduction in serum LPS.
|
3 months and 12 months post liver transplant
|
Measurement of mRNA markers of the fibrosis cascade
Tidsramme: 3 months and 12 months post liver transplant
|
Comparison of mRNA markers of the fibrosis cascade between groups in the 3 month and 1 year post-LT liver biopsies.
|
3 months and 12 months post liver transplant
|
Number of adverse events (severe and non-serious)
Tidsramme: Up to 30 days post study participation
|
Evaluation of the safety of Rifaximin compared to placebo in early post liver transplant patients, by assessing adverse events and severe adverse events experienced by the patients during the Rifaximin treatment course.
|
Up to 30 days post study participation
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Elizabeth Verna, MD, Columbia University
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Patologiske processer
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Leversygdomme
- Flaviviridae infektioner
- Hepatitis, viral, menneskelig
- Fibrose
- Hepatitis
- Hepatitis C
- Anti-infektionsmidler
- Gastrointestinale midler
- Antibakterielle midler
- Rifaximin
Andre undersøgelses-id-numre
- AAAI4155
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hepatitis C
-
Beni-Suef UniversityAfsluttetKronisk hepatitis C virusinfektionEgypten
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsTrukket tilbageKronisk hepatitis C virusinfektionIsrael
-
Hadassah Medical OrganizationUkendtKronisk hepatitis C virusinfektionIsrael
-
Trek Therapeutics, PBCAfsluttetKronisk hepatitis C | Hepatitis C genotype 1 | Hepatitis C (HCV) | Hepatitis C viral infektionForenede Stater, New Zealand
-
Trek Therapeutics, PBCAfsluttetKronisk hepatitis C | Hepatitis C (HCV) | Hepatitis C genotype 4 | Hepatitis C viral infektionForenede Stater
-
Tripep ABInovio PharmaceuticalsUkendtKronisk hepatitis C virusinfektionSverige
-
Humanity and Health Research CentreBeijing 302 HospitalAfsluttetKronisk hepatitis C-infektionKina
-
AbbVieAfsluttetKronisk hepatitis C | Hepatitis C (HCV) | Hepatitis C genotype 1a
-
AbbVieAfsluttetKronisk hepatitis C | Hepatitis C (HCV) | Hepatitis C genotype 1a
-
AbbVie (prior sponsor, Abbott)AfsluttetKronisk hepatitis C | Hepatitis C genotype 1 | Hepatitis C (HCV)Forenede Stater, Australien, Canada, Frankrig, Tyskland, New Zealand, Puerto Rico, Spanien, Det Forenede Kongerige
Kliniske forsøg med Rifaximin
-
Bausch Health Americas, Inc.AfsluttetIrritabel tyktarm med diarréForenede Stater, Det Forenede Kongerige, Tyskland
-
Bausch Health Americas, Inc.AfsluttetSeglcellesygdomForenede Stater, Canada, Kenya
-
Bausch Health Americas, Inc.AfsluttetLevercirrhoseForenede Stater, Den Russiske Føderation
-
Shanghai Changzheng HospitalUkendt
-
National University Hospital, SingaporeNational University, SingaporeAfsluttetIrritabel tyktarm med diarréSingapore
-
Alfasigma S.p.A.AfsluttetDivertikulitFrankrig, Tyskland, Italien, Holland, Spanien, Det Forenede Kongerige
-
SandozAfsluttetRejsendes diarréMexico
-
Sun Yat-sen UniversityRekrutteringHepatisk encefalopati | Hepatitis B | HBV | Virkning af lægemiddel | Leversvigt, akut på kronisk | RifaximinKina
-
Bausch Health Americas, Inc.Aktiv, ikke rekrutterendeHepatisk encefalopatiForenede Stater, Australien, Canada, Puerto Rico
-
Johns Hopkins Bloomberg School of Public HealthNaval Medical Research Center; Uniformed Services University of the Health...AfsluttetDiarré | Dysenteri | Enterisk CampylobacteriosisForenede Stater